vs
Side-by-side financial comparison of Chemours Co (CC) and Hologic (HOLX). Click either name above to swap in a different company.
Chemours Co is the larger business by last-quarter revenue ($1.3B vs $1.0B, roughly 1.3× Hologic). Hologic runs the higher net margin — 17.1% vs -3.5%, a 20.6% gap on every dollar of revenue. On growth, Hologic posted the faster year-over-year revenue change (2.5% vs -2.1%). Hologic produced more free cash flow last quarter ($215.2M vs $92.0M). Over the past eight quarters, Hologic's revenue compounded faster (1.5% CAGR vs -1.2%).
The Chemours Company is an American chemical company that was founded in July 2015 as a spin-off from DuPont. It has its corporate headquarters in Wilmington, Delaware, United States. Chemours is the manufacturer of Teflon, the brand name of polytetrafluoroethylene (PTFE), known for its anti-stick properties. It also produces titanium dioxide and refrigerant gases.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
CC vs HOLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $1.0B |
| Net Profit | $-47.0M | $179.1M |
| Gross Margin | 11.7% | 56.0% |
| Operating Margin | — | 22.6% |
| Net Margin | -3.5% | 17.1% |
| Revenue YoY | -2.1% | 2.5% |
| Net Profit YoY | -261.5% | -10.9% |
| EPS (diluted) | $-0.32 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3B | $1.0B | ||
| Q3 25 | $1.5B | $1.0B | ||
| Q2 25 | $1.6B | $1.0B | ||
| Q1 25 | $1.4B | $1.0B | ||
| Q4 24 | $1.4B | $1.0B | ||
| Q3 24 | $1.5B | $988.0M | ||
| Q2 24 | $1.6B | $1.0B | ||
| Q1 24 | $1.4B | $1.0B |
| Q4 25 | $-47.0M | $179.1M | ||
| Q3 25 | $46.0M | $187.2M | ||
| Q2 25 | $-380.0M | $194.9M | ||
| Q1 25 | $-5.0M | $-17.4M | ||
| Q4 24 | $-13.0M | $201.0M | ||
| Q3 24 | $-32.0M | $178.6M | ||
| Q2 24 | $60.0M | $194.5M | ||
| Q1 24 | $54.0M | $169.9M |
| Q4 25 | 11.7% | 56.0% | ||
| Q3 25 | 15.6% | 55.6% | ||
| Q2 25 | 17.2% | 56.3% | ||
| Q1 25 | 17.3% | 37.5% | ||
| Q4 24 | 19.4% | 56.8% | ||
| Q3 24 | 19.0% | 56.4% | ||
| Q2 24 | 19.8% | 55.4% | ||
| Q1 24 | 20.9% | 53.3% |
| Q4 25 | — | 22.6% | ||
| Q3 25 | 2.5% | 22.6% | ||
| Q2 25 | -15.4% | 24.9% | ||
| Q1 25 | — | -0.7% | ||
| Q4 24 | -0.1% | 22.5% | ||
| Q3 24 | -2.1% | 23.3% | ||
| Q2 24 | 4.4% | 24.1% | ||
| Q1 24 | 5.1% | 20.7% |
| Q4 25 | -3.5% | 17.1% | ||
| Q3 25 | 3.1% | 17.8% | ||
| Q2 25 | -23.5% | 19.0% | ||
| Q1 25 | -0.4% | -1.7% | ||
| Q4 24 | -1.0% | 19.7% | ||
| Q3 24 | -2.1% | 18.1% | ||
| Q2 24 | 3.9% | 19.2% | ||
| Q1 24 | 4.0% | 16.7% |
| Q4 25 | $-0.32 | $0.79 | ||
| Q3 25 | $0.31 | $0.84 | ||
| Q2 25 | $-2.53 | $0.86 | ||
| Q1 25 | $-0.03 | $-0.08 | ||
| Q4 24 | $-0.07 | $0.87 | ||
| Q3 24 | $-0.22 | $0.75 | ||
| Q2 24 | $0.39 | $0.82 | ||
| Q1 24 | $0.36 | $0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $670.0M | $2.4B |
| Total DebtLower is stronger | $4.1B | $2.5B |
| Stockholders' EquityBook value | $250.0M | $5.2B |
| Total Assets | $7.4B | $9.2B |
| Debt / EquityLower = less leverage | 16.40× | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $670.0M | $2.4B | ||
| Q3 25 | $613.0M | $2.2B | ||
| Q2 25 | $502.0M | $1.9B | ||
| Q1 25 | $464.0M | $1.6B | ||
| Q4 24 | $713.0M | $2.0B | ||
| Q3 24 | $596.0M | $2.3B | ||
| Q2 24 | $604.0M | $2.4B | ||
| Q1 24 | $746.0M | $2.2B |
| Q4 25 | $4.1B | $2.5B | ||
| Q3 25 | $4.1B | $2.5B | ||
| Q2 25 | $4.1B | $2.5B | ||
| Q1 25 | $4.1B | $2.5B | ||
| Q4 24 | $4.1B | $2.5B | ||
| Q3 24 | $4.0B | $2.5B | ||
| Q2 24 | $4.0B | $2.5B | ||
| Q1 24 | $4.0B | $2.6B |
| Q4 25 | $250.0M | $5.2B | ||
| Q3 25 | $274.0M | $5.0B | ||
| Q2 25 | $228.0M | $4.8B | ||
| Q1 25 | $566.0M | $4.6B | ||
| Q4 24 | $571.0M | $4.8B | ||
| Q3 24 | $643.0M | $5.1B | ||
| Q2 24 | $714.0M | $5.0B | ||
| Q1 24 | $753.0M | $4.8B |
| Q4 25 | $7.4B | $9.2B | ||
| Q3 25 | $7.5B | $9.0B | ||
| Q2 25 | $7.5B | $8.8B | ||
| Q1 25 | $7.4B | $8.5B | ||
| Q4 24 | $7.5B | $8.7B | ||
| Q3 24 | $7.5B | $9.2B | ||
| Q2 24 | $7.2B | $8.9B | ||
| Q1 24 | $8.0B | $8.7B |
| Q4 25 | 16.40× | 0.48× | ||
| Q3 25 | 14.96× | 0.50× | ||
| Q2 25 | 17.99× | 0.52× | ||
| Q1 25 | 7.18× | 0.55× | ||
| Q4 24 | 7.11× | 0.53× | ||
| Q3 24 | 6.20× | 0.49× | ||
| Q2 24 | 5.53× | 0.51× | ||
| Q1 24 | 5.27× | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $137.0M | $229.9M |
| Free Cash FlowOCF − Capex | $92.0M | $215.2M |
| FCF MarginFCF / Revenue | 6.9% | 20.5% |
| Capex IntensityCapex / Revenue | 3.4% | 1.4% |
| Cash ConversionOCF / Net Profit | — | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | $51.0M | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $137.0M | $229.9M | ||
| Q3 25 | $146.0M | $355.1M | ||
| Q2 25 | $93.0M | $343.3M | ||
| Q1 25 | $-112.0M | $169.4M | ||
| Q4 24 | $138.0M | $189.3M | ||
| Q3 24 | $139.0M | $367.0M | ||
| Q2 24 | $-620.0M | $405.8M | ||
| Q1 24 | $-290.0M | $292.4M |
| Q4 25 | $92.0M | $215.2M | ||
| Q3 25 | $105.0M | $341.4M | ||
| Q2 25 | $50.0M | $330.5M | ||
| Q1 25 | $-196.0M | $153.9M | ||
| Q4 24 | $29.0M | $172.5M | ||
| Q3 24 | $63.0M | $350.6M | ||
| Q2 24 | $-693.0M | $385.3M | ||
| Q1 24 | $-392.0M | $279.6M |
| Q4 25 | 6.9% | 20.5% | ||
| Q3 25 | 7.0% | 32.5% | ||
| Q2 25 | 3.1% | 32.3% | ||
| Q1 25 | -14.3% | 15.3% | ||
| Q4 24 | 2.1% | 16.9% | ||
| Q3 24 | 4.2% | 35.5% | ||
| Q2 24 | -44.6% | 38.1% | ||
| Q1 24 | -28.8% | 27.5% |
| Q4 25 | 3.4% | 1.4% | ||
| Q3 25 | 2.7% | 1.3% | ||
| Q2 25 | 2.7% | 1.3% | ||
| Q1 25 | 6.1% | 1.5% | ||
| Q4 24 | 8.0% | 1.6% | ||
| Q3 24 | 5.0% | 1.7% | ||
| Q2 24 | 4.7% | 2.0% | ||
| Q1 24 | 7.5% | 1.3% |
| Q4 25 | — | 1.28× | ||
| Q3 25 | 3.17× | 1.90× | ||
| Q2 25 | — | 1.76× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.94× | ||
| Q3 24 | — | 2.05× | ||
| Q2 24 | -10.33× | 2.09× | ||
| Q1 24 | -5.37× | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CC
| Titanium Technologies | $563.0M | 42% |
| Thermal And Specialized Solutions | $443.0M | 33% |
| Advanced Performance Materials | $312.0M | 23% |
| Other Non-Reportable Segment | $12.0M | 1% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
